

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: markspencer

Timestamp: Fri Jul 06 13:30:21 EDT 2007

=====

\*\*\*\*\*

Reviewer Comments:

For SEQ ID # 1 and 11, a Xaa can only represent a single amino acid, not a group of amino acids or a motif. Many of the SEQ ID numbers have incomplete features with nothing provided in the <223> numeric identifier. The numbering of the amino acids, in all of the sequences, is not aligned properly.

\*\*\*\*\*

Application No: 10573576 Version No: 1.0

Input Set:

Output Set:

Started: 2007-07-05 13:02:56.585  
Finished: 2007-07-05 13:03:00.275  
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 690 ms  
Total Warnings: 55  
Total Errors: 37  
No. of SeqIDs Defined: 30  
Actual SeqID Count: 30

Error code	Error Description
W 333	tabs used in amino acid numbering SEQID (1)
W 333	tabs used in amino acid numbering SEQID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 201	Mandatory field data missing in <223> in SEQ ID (2)
W 333	tabs used in amino acid numbering SEQID (2)
W 333	tabs used in amino acid numbering SEQID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 201	Mandatory field data missing in <223> in SEQ ID (3)
W 333	tabs used in amino acid numbering SEQID (3)
W 333	tabs used in amino acid numbering SEQID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 201	Mandatory field data missing in <223> in SEQ ID (4)
W 333	tabs used in amino acid numbering SEQID (4)
W 333	tabs used in amino acid numbering SEQID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (5)
E 201	Mandatory field data missing in <223> in SEQ ID (5)
W 333	tabs used in amino acid numbering SEQID (5)
W 333	tabs used in amino acid numbering SEQID (5)
E 257	Invalid sequence data feature in <221> in SEQ ID (6)
E 201	Mandatory field data missing in <223> in SEQ ID (6)

**Input Set:**

**Output Set:**

**Started:** 2007-07-05 13:02:56.585  
**Finished:** 2007-07-05 13:03:00.275  
**Elapsed:** 0 hr(s) 0 min(s) 3 sec(s) 690 ms  
**Total Warnings:** 55  
**Total Errors:** 37  
**No. of SeqIDs Defined:** 30  
**Actual SeqID Count:** 30

Error code	Error Description
W 333	tabs used in amino acid numbering SEQID (6)
W 333	tabs used in amino acid numbering SEQID (6)
E 257	Invalid sequence data feature in <221> in SEQ ID (7)
E 201	Mandatory field data missing in <223> in SEQ ID (7)
W 333	tabs used in amino acid numbering SEQID (7)
W 333	tabs used in amino acid numbering SEQID (7)
E 257	Invalid sequence data feature in <221> in SEQ ID (8)
E 201	Mandatory field data missing in <223> in SEQ ID (8)
W 333	tabs used in amino acid numbering SEQID (8)
W 333	tabs used in amino acid numbering SEQID (8)
E 257	Invalid sequence data feature in <221> in SEQ ID (9)
E 201	Mandatory field data missing in <223> in SEQ ID (9)
W 333	tabs used in amino acid numbering SEQID (9)
W 333	tabs used in amino acid numbering SEQID (9)
E 257	Invalid sequence data feature in <221> in SEQ ID (10)
E 201	Mandatory field data missing in <223> in SEQ ID (10)
W 333	tabs used in amino acid numbering SEQID (10)
W 333	tabs used in amino acid numbering SEQID (10) This error has occurred more than 20 times, will not be displayed
E 257	Invalid sequence data feature in <221> in SEQ ID (24)
E 201	Mandatory field data missing in <223> in SEQ ID (24)
E 257	Invalid sequence data feature in <221> in SEQ ID (24)
E 257	Invalid sequence data feature in <221> in SEQ ID (25)

**Input Set:**

**Output Set:**

**Started:** 2007-07-05 13:02:56.585  
**Finished:** 2007-07-05 13:03:00.275  
**Elapsed:** 0 hr(s) 0 min(s) 3 sec(s) 690 ms  
**Total Warnings:** 55  
**Total Errors:** 37  
**No. of SeqIDs Defined:** 30  
**Actual SeqID Count:** 30

Error code	Error Description
E 257	Invalid sequence data feature in <221> in SEQ ID (25)
E 201	Mandatory field data missing in <223> in SEQ ID (25)
E 257	Invalid sequence data feature in <221> in SEQ ID (26)
E 257	Invalid sequence data feature in <221> in SEQ ID (27)
E 201	Mandatory field data missing in <223> in SEQ ID (27)
E 257	Invalid sequence data feature in <221> in SEQ ID (28)
E 201	Mandatory field data missing in <223> in SEQ ID (28)
E 257	Invalid sequence data feature in <221> in SEQ ID (29)
E 201	Mandatory field data missing in <223> in SEQ ID (29)
E 257	Invalid sequence data feature in <221> in SEQ ID (29)
E 201	Mandatory field data missing in <223> in SEQ ID (29)
E 257	Invalid sequence data feature in <221> in SEQ ID (30)
E 201	Mandatory field data missing in <223> in SEQ ID (30)
E 257	Invalid sequence data feature in <221> in SEQ ID (30) This error has occurred more than 20 times, will not be displayed
E 201	Mandatory field data missing in <223> in SEQ ID (30)

# SEQUENCE LISTING

<110> THERAPTOSIS S.A.

<120> Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics

<130> CP/61114-PCT

<140> 10573576

<141> 2007-07-05

<150> FR 02 11 270

<151> 2003-09-25

<160> 30

<170> PatentIn version 3.1

<210> 1

<211> 26

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> either a G or a GG, the amino-terminal end of which is free, alkylated, acylated, or in particular acetylated, or contains a labelling group, such as the biotinyl group.

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> either a C, in which case X in the 2-position = X in the 9-position, the two Cs then being connected by a disulphide bridge, or X in the 2-position is capable of forming a lactam bridge with X in the 4-position, one of X in the 2-position or X in the 9-position being an amino acid bearing an acid group, such as A or D, the other bearing an amino function, such as Q or N.

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> either a C, in which case X in the 2-position = X in the 9-position, the two Cs then being connected by a disulphide bridge, or X in the 2-position is capable of forming a lactam bridge with X in the 9-position, one of X in the 2-position or X in the 9-position being an amino acid bearing an acid group, such as A or D, the other bearing an amino function, such as Q or N.

<220>

<221> MISC\_FEATURE

<222> (9)..(9)

<223> either a C, in which case X in the 2-position = X in the 9-position, the two Cs then being connected by a disulphide bridge, or X in the 2-position is capable of forming a lactam bridge with X in the 4-position, one of X in the 2-position or X in the 9-position being an amino acid bearing an acid group,

such as A or D, the other bearing an amino function, such as Q or N.

<220>

<221> MISC\_FEATURE

<222> (17)..(17)

<223> either an R motif or a K motif.

<220>

<221> MISC\_FEATURE

<222> (21)..(21)

<223> either an R motif or a K motif.

<220>

<221> MISC\_FEATURE

<222> (24)..(24)

<223> either an R motif or a K motif.

<220>

<221> MISC\_FEATURE

<222> (26)..(26)

<223> is an aliphatic amino acid, the C-terminal end of which is amidated.

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> either an M motif or a norleucine motif.

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> either a motif, or a succession of two di-, tri- or tetrapeptide motifs composed of G or of a combination of G and of S, such as GG, GGG, GGGG, GGS, GGGS or GGS GGS, or else X in the 5-position is a C motif, the side chain of which serves as a point for covalent bonding with a 3-nitro-2-pyridinesulphenyl group, etc.

<400> 1

Xaa Xaa Arg Gly Asp Xaa Phe Gly Xaa Xaa Leu Leu Phe Ile His Phe  
1 5 10 15

Xaa Ile Gly Ser Xaa His Ser Xaa Ile Xaa  
20 25

<210> 2

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<400> 2

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 3

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<400> 3

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Arg Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 4

<211> 27

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<400> 4

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Phe Ile His  
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 5

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<400> 5

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Ser Leu Phe Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 6  
<211> 28  
<212> PRT  
<213> Human HIV

<220>  
<221> DISULPHIDE  
<222> (3)..(10)  
<223>

<400> 6

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 7  
<211> 29  
<212> PRT  
<213> Human HIV

<220>  
<221> DISULPHIDE  
<222> (3)..(10)  
<223>

<220>  
<221> MISC\_FEATURE  
<222> (19)..(19)  
<223> NR representing an N-alkylarginine motif

<400> 7

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Asn Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 8  
<211> 28  
<212> PRT  
<213> Human HIV

<220>  
<221> DISULPHIDE  
<222> (3)..(10)  
<223>

<400> 8

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Arg  
1 5 10 15



His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 9

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<400> 9

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 10

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(9)

<223>

<400> 10

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Arg  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 11

<211> 8

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> the RGD motif via a lactam bridge between the amino acids X (X)-C-O-NH-(X'),  
X and X' being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (8)..(8)

<223> the RGD motif via a lactam bridge between the amino acids X (X)-C-O-NH-(X'),  
X and X' being amino acids such that one bears an acid group and the other bears an amine

<400> 11

Xaa Arg Gly Asp Met Phe Gly Xaa

1 5

<210> 12

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 12

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile

1 5 10 15

His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly

20 25

<210> 13

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 13

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile

1 5 10 15

Phe Phe Arg Ile Gly Cys Arg Phe Ser Arg Ile Gly

20 25

<210> 14

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 14

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 15

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 15

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Arg Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 16

<211> 27

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 16

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Phe Ile His  
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 17  
<211> 28  
<212> PRT  
<213> Human HIV

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 17

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Ser Leu Phe Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 18  
<211> 28  
<212> PRT  
<213> Human HIV

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 18

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 19

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (19)..(19)

<223> NR representing an N-alkylarginine motif

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 19

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 20

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 20

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Arg  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 21

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 21

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 22

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 22

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Arg  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 23

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids  
such that one bears an acid group and the other bears an amine

<400> 23

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 24

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<220>

<221> MOD\_RES

<222> (28)..(28)

<223> AMIDATION

<400> 24

Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 25

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MOD\_RES

<222> (28)..(28)

<223> AMIDATION

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<400> 25

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile  
1 5 10 15

His Phe Ala Ile Gly Ser Arg His Ser Ala Ile Gly  
20 25

<210> 26

<211> 27

<212> PRT

<213> Human HIV

<220>

<221> MOD\_RES

<222> (27)..(27)

<223> AMIDATION

<400> 26

Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Leu Leu Phe Ile His  
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
20 25

<210> 27

<211> 16

<212> PRT

<213> Human HIV

<220>

<221> MOD\_RES

<222> (16)..(16)

<223>

<400> 27

Leu Leu Phe Ile His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly  
1 5 10 15

<210> 28

<211> 12

<212> PRT

<213> Human HIV

<220>

<221> MOD\_RES

<222> (12)..(12)

<223>

<400> 28



Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly  
1 5 10

<210> 29

<211> 12

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<220>

<221> MOD\_RES

<222> (12)..(12)

<223>

<400> 29

Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly  
1 5 10

<210> 30

<211> 12

<212> PRT

<213> Human HIV

<220>

<221> DISULPHIDE

<222> (3)..(10)

<223>

<220>

<221> MOD\_RES

<222> (12)..(12)

<223>

<400> 30

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly  
1 5 10